New Treatment Options for Pulmonary Arterial Hypertension — The First Selective IP-receptor Agonist Selexipag

Cardiovascular Therapy and Prevention (Russian Federation)- Russian Federation

doi 10.15829/1728-8800-2019-6-80-87

Full Text

Abstract

Available in

Date

Authors

Publisher

Silicea - Poligraf, LLC

Related search

Selexipag for the Treatment of Pulmonary Arterial Hypertension

Expert Opinion on Pharmacotherapy
MedicinePharmacology
2016English

Selexipag for the Treatment of Pulmonary Arterial Hypertension

Expert Opinion on Pharmacotherapy
MedicinePharmacology
2014English

Contraceptive Options for the Patient With Pulmonary Arterial Hypertension

Advances in Pulmonary Hypertension
2011English

Endothelin Receptor Antagonism: A New Era in the Treatment of Pulmonary Arterial Hypertension

Advances in Pulmonary Hypertension
2002English

Smooth Muscle Proliferation and Role of the Prostacyclin (IP) Receptor in Idiopathic Pulmonary Arterial Hypertension

American Journal of Respiratory and Critical Care Medicine
PulmonaryCritical CareRespiratory MedicineIntensive Care Medicine
2010English

The New Endothelin Receptor Antagonist Macitentan: Prospects for Therapy of Pulmonary Arterial Hypertension

Terapevticheskii Arkhiv
Internal MedicineEndocrinologyMetabolismDiabetes
2016English

Pulmonary Arterial Hypertension After Ibuprofen Treatment in the First Week of Life?

Journal of Pediatrics
Child HealthPediatricsPerinatology
2017English

Future Perspectives for the Treatment of Pulmonary Arterial Hypertension

Advances in Pulmonary Hypertension
2009English

Determining the Value Contribution of Selexipag for the Treatment of Pulmonary Arterial Hypertension (PAH) in Spain Using Reflective Multi-Criteria Decision Analysis (MCDA)

Orphanet Journal of Rare Diseases
MedicineGeneticsPharmacology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy